Clinical Trial Update: Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment. [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the efficacy and safety of CX516 in elderly participants with mild cognitive impairment has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment

Drugs mentioned

• CX516

Snippet

Sponsor: RespireRx | Conditions: Mild Cognitive Impairment | Phase 2 | Status: COMPLETED | Results posted: 2018-07-23